45Z Finally Materializes, EBITDA Turns Positive, and the Stock Rips 50% — But $362M Due in 48 Days Means the Thesis Still Comes Down to One Phone Call With Third Eye Capital

Results vs. Consensus

Quality of Beat/Miss

• Revenue: The 32% product revenue miss is the fourth consecutive miss of similar magnitude (Q1: -27%, Q2: -33%, Q3: -33%, Q4: -32%). However, Q4's miss is qualitatively different. Product revenue of $43.3M was depressed by India's collapse to ~$3.3M (from $14.5M in Q3) and lower ethanol volumes — factors the Street could have anticipated. More importantly, the $10.4M in production tax credits represents a new recurring revenue stream that consensus models haven't incorporated. Including credits, total income of $53.7M narrows the miss to 16%. As analysts recalibrate models for 45Z, the "miss" framing should fade.
• EPS and profitability: The ($0.08) EPS is the best quarter since we initiated coverage — dramatically better than Q1's ($0.47), Q2's ($0.41), and Q3's ($0.37). But the improvement was driven by two non-operational items: $10.4M in 45Z production tax credits at the gross profit line and an $11.4M income tax benefit from tax credit sales below the line. Together, these two items account for ~$22M of the ~$18M QoQ improvement in net loss (from ($23.7M) to ($5.3M)). Strip out the 45Z credits: product revenue minus COGS is still ($2.6M) negative. Strip out the tax benefit: net loss would have been ~($16.7M), roughly in line with Q3. The underlying product economics haven't yet turned positive — that's the MVR story (H2 2026). The EPS beat is real, but its quality is lower than the headline suggests.
• EBITDA quality: The $1.9M positive EBITDA is a legitimate milestone but modest in absolute terms. On an FY2025 basis, Adj. EBITDA was ($19.6M) — meaning Q4's $1.9M offset only a fraction of the year's accumulated losses. The progression (Q1: ($13.2M), Q2: ($5.8M), Q3: ($5.0M), Q4: $1.9M) shows the trajectory is strongly positive, but sustainability depends on 45Z continuing to be recognized and India recovering.

FY2025 Full Year Summary

FY2025 was a year of two halves. The first three quarters produced cumulative revenue of $154.3M, gross losses, and negative EBITDA — the worst operational stretch in recent company history, driven by India's collapse and the absence of 45Z monetization. Q4 reversed the trajectory with the first positive gross profit, positive EBITDA, and the first EPS beat, but could not rescue the full-year numbers. The 26% revenue decline is almost entirely attributable to India ($93M → $29.7M, a $63M swing) and the absence of FY2024's higher ethanol volumes. The one unambiguously positive FY2025 story is Dairy RNG's emergence as a profitable, scaling business platform.

Quarterly Financial Progression

The profitability trajectory is unmistakable: gross margin improved from -12% to +14% over four quarters, EPS improved from ($0.47) to ($0.08), and EBITDA went from ($13M) to $2M positive. But product revenue went backwards in Q4 — the India OMC delay pattern repeated, erasing the Q2-Q3 ramp. The Q4 story is one of mix shift: less product revenue but new production tax credit revenue, lower COGS on lower product volumes, and RNG's emergence as a profit center. This is a qualitatively better earnings profile even if the top line disappointed.

Segment Performance

Dairy RNG: The Star of the Quarter

Dairy RNG has transitioned from a development-stage project to the company's most profitable segment. Q4 segment net income of $12.2M was a landmark — this single segment generated more profit in Q4 than the entire company lost. For FY2025, Dairy RNG produced 405K MMBtu (+34% YoY from 302K), contributed $15M in product revenue and $5M in 45Z credits, and sold $18M in investment tax credits from dairy digesters. The segment's FY2025 net income of $6.9M makes it the only profitable business line.

The economics are accelerating from multiple vectors: LCFS credit prices recovered from $40 to $70, with management expecting $100 this year and $150+ next year against a regulatory cap of $268. CARB approved 7 LCFS pathways with an average carbon intensity score of negative 380 (vs. the default -150), meaning each MMBtu generates significantly more credits. With 15 additional digesters contracted ($27M with Centuri) expanding the fleet from 12 to 27, the platform is targeting 1M MMBtu by year-end 2026 and 1.6M MMBtu at full buildout — implying $250M in annual revenue at scale.

Assessment: This is the segment that justifies continued interest in the equity. At $70/credit and improving CI scores, RNG economics are attractive even before the MVR-driven ethanol CI improvements feed through. The 45Z + LCFS combination on dairy RNG creates a revenue stack that management described as "$7/gallon equivalent" — if realized at 1M MMBtu scale, this segment alone could generate $50M+ in annual cash flow. The risk is execution on the digester buildout and continued LCFS price recovery.

India Biodiesel: Third Collapse

India was the quarter's biggest disappointment. After a promising ramp from $0 (Q1) to $11.9M (Q2) to $14.5M (Q3), Q4 revenue collapsed to an estimated ~$3.3M. FY2025 volumes of 21K metric tons were 72% below FY2024's 74K, and capacity utilization of 14% was the worst full-year reading in the facility's history. The culprit was the same pattern that has plagued India for four quarters: OMC (Oil Marketing Company) tender delays halting deliveries.

Deliveries resumed in late December 2025, and a new $24M OMC allocation was secured in February 2026 — the latest in a series of orders ($31M prior) that consistently fail to translate into steady production. The plant's 80M gallon/year capacity at Kakinada represents enormous latent value, but that value has been latent for 12 months.

Assessment: India is the segment where management credibility is weakest. Each quarter brings a new OMC allocation announcement; each quarter brings another utilization collapse. We are no longer willing to model India above $10M/quarter until it delivers two consecutive quarters above that threshold. The India IPO, still targeting 2026 with no DRHP filed, cannot be valued until the underlying business demonstrates stable production. The one genuine positive: geopolitical tailwinds from Trump tariffs on Russian crude are pushing India toward higher domestic biodiesel mandates (0.5% to 5% blend target), which could structurally improve OMC demand if implemented.

California Ethanol: Stable but Awaiting MVR Uplift

FY2025 ethanol product revenue of $153.2M was modestly below FY2024's $162M, reflecting lower production volumes (57M vs. 61M gallons) partially offset by higher pricing ($2.03 vs. $1.96/gal). The Keyes plant continued operating at approximately 90% utilization through Q4. The $5.1M in 45Z production tax credits on ethanol represents the first monetization of the federal clean fuel credit for this segment.

Assessment: Keyes is the cash-flow engine in waiting. The combination of MVR completion (Q3-Q4 2026), E15 market expansion (+600M gal/yr in California), and 45Z credits creates a scenario where this plant could generate $48M/year in combined 45Z + LCFS revenue post-MVR (management's $4M/month estimate) vs. ~$12M/year currently. That's a $36M/year step-up. But until MVR is operational, Keyes is a breakeven-to-slightly-profitable ethanol plant in a commodity market.

Key Topics & Management Commentary

Overall Management Tone: The most upbeat in four quarters — and for the first time, partially justified. CEO McAfee's narrative of "positioned for significant growth" was the same as Q3, but Q4 delivered tangible evidence: positive EBITDA, 45Z monetization, and MVR construction underway. The tone shift from prior quarters was less about what management said and more about having results that supported the messaging. However, the conspicuous absence of any detail on Third Eye Capital debt resolution — a $362M obligation due within weeks — remains a glaring gap between the forward-looking optimism and the near-term financial reality.

1. 45Z: Twelve Months Late, But It Arrived

After three consecutive quarters of promises and zero delivery, Aemetis recognized $10.4M in 45Z production tax credits in FY2025 — $5.1M from ethanol and $5.0M from Dairy RNG. More importantly, the company completed a proof-of-concept transaction in December 2025, selling $17M in federal clean energy tax credits (including approximately $5M from 45Z RNG credits) for net proceeds of ~$15M. This demonstrated that 45Z credits have real, transferable monetary value.

The policy backdrop strengthened materially in Q4. Treasury issued proposed 45Z regulations on February 4, 2026, which notably removed the indirect land use change (ILUC) penalty for corn ethanol — a significant positive for Aemetis's CI score calculations. The DOE released the 45ZCF-GREET model for emissions rate calculations. However, these are proposed rules, not final: the comment period runs through April 6, 2026, with a public hearing scheduled for May 28.

"Dairy RNG and swine RNG are the big winners under 45Z" with potential "$7 per gallon equivalent revenue." — Eric McAfee, CEO

Assessment: 45Z's arrival changes the investment thesis. What was a 50/50 probability in our Q3 model is now a demonstrated revenue stream with a $15M proof-of-concept sale. The ILUC removal from the proposed regulations is a tailwind that could increase ethanol credit values. Management expects an additional $10.5M Section 45C ITC in 2026 (IRS/DOE approved). Post-MVR, the combined 45Z + LCFS revenue on ethanol alone is estimated at $3M/month additional (~$36M/year incremental). The remaining risk is that proposed rules could be weakened during the comment period, but the trajectory is clearly favorable.

2. MVR: Over 50% Built, $32M/Year Catalyst on Track

MVR is no longer a promise — it's steel in the ground. Air permits were received December 2, 2025 from the San Joaquin Valley Air Pollution Control District. Construction is underway with NPL Construction (Centuri), and over 50% of the ~$40M total project capital has been spent (revised upward from the original $30M estimate). Management guided to initial contribution in Q3 2026 with full impact in Q4 2026.

"Contribution should hit us in third quarter, be in full place in the fourth quarter." — Management, Q4 earnings call

The economics remain compelling: 80% reduction in natural gas usage, double-digit carbon intensity reduction (improving LCFS credit generation), and the combined 45Z + LCFS revenue of ~$4M/month post-installation. Funding of ~$19.7M from IRS/DOE grants, California Energy Commission, and PG&E covers roughly half the cost with no equity dilution.

Assessment: MVR is the highest-conviction near-term catalyst and the one most within management's control. With >50% capital deployed, the completion risk has shifted from "will they build it?" to "will it work as modeled?" The cost escalation from $30M to ~$40M is notable but manageable given grant coverage. We continue to model first-year MVR contribution at $15-20M (haircut to the $32M estimate), with full run-rate in 2027. The critical path item is now the Q3-Q4 2026 construction timeline — any delay pushes both MVR cash flow and the debt refinancing narrative.

3. The Debt Wall: $362M in 48 Days

The most consequential non-answer of the quarter. Third Eye Capital holds ~$247.9M in facilities now classified as "due on demand" — meaning Third Eye can call the debt at any time. Separately, the Series A Preferred Unit redemption of $114.7M was extended from December 31, 2025 to April 30, 2026, via a February 4, 2026 amendment. If unredeemed by April 30, it converts to a credit agreement at 16% (or Prime + 10%) maturing May 1, 2027.

Management's stated strategy is to refinance "in the first half of 2026 as recurring tax credit revenues become clearer." But this is the same circular dependency we identified in Q3: refinancing requires demonstrated 45Z cash flow, which requires time, which requires the debt not being called.

"Focus is on scaling production, monetizing environmental credit values, completing the India IPO, and long-term refinancing of existing debt... aiming for completion in the first half of 2026 as recurring tax credit revenues become clearer." — Eric McAfee, CEO

Assessment: The Series A extension to April 30 is a minor positive — it demonstrates willingness to negotiate rather than enforce. But the core Third Eye debt remains due on demand with an Altman Z-Score of -5.08, current liabilities exceeding total assets by $111.5M, and a $306.8M stockholders' deficit. The math is stark: $362M due in the next 48 days, $4.9M cash, and no disclosed refinancing term sheet. Our base case remains that Third Eye extends (they have no incentive to force liquidation of complex renewable energy assets at distressed prices), but we lower our survival probability from 70-75% (Q3) to a more nuanced assessment: 75-80% probability that the company survives the next 12 months through extensions and partial monetization, but only 40-50% probability that a clean refinancing occurs that meaningfully improves the capital structure. The difference matters: extension at 16-21% rates preserves the equity but doesn't create shareholder value; refinancing at market rates does.

4. LCFS Credit Price Recovery

One of the most under-discussed positives: LCFS credit prices have recovered from $40 eight months ago to $70 currently, with management expecting $100 this year and $150+ next year. The regulatory cap is $268. For a company whose core assets produce low-CI fuels (ethanol at Keyes, RNG from dairy digesters), LCFS pricing is as important as commodity pricing. At $70/credit, the economics are workable; at $100+, they become compelling. With 7 CARB-approved pathways at an average CI of negative 380, Aemetis generates more LCFS credits per unit of production than nearly any competitor.

Assessment: LCFS recovery is a significant macro tailwind that compounds the 45Z benefit. The two credit systems (federal 45Z and California LCFS) stack on top of each other, creating a revenue layer that is largely policy-driven and independent of commodity markets. If LCFS reaches $100 as management projects, the incremental value per LCFS credit pathway is substantial — this is the mechanism through which MVR's carbon intensity reduction converts to cash. We model LCFS at $75 for 2026 (conservative vs. $100 management target).

5. FY2026 Outlook: Bold Claims, No Numbers

Management described FY2026 operations as expected to be "significantly in excess of 2025" in cash flow, but declined to provide specific EBITDA, revenue, or cash flow guidance, citing regulatory uncertainty around the GREET model timing and LCFS pricing. The strategic priorities for 2026 are: (1) scale RNG to 1M MMBtu run rate, (2) complete MVR installation, (3) monetize 45Z + LCFS at higher rates, (4) complete India IPO, and (5) refinance debt.

Street consensus for FY2026 sits at $594.9M in revenue and ($0.18) EPS, implying a massive ramp that almost certainly includes SAF plant revenue that management has not confirmed will materialize. FY2027 consensus of $860.9M and $0.77 EPS would be the first profitable full year.

Assessment: The $595M consensus is detached from reality. Achievable FY2026 revenue, in our estimation: California ethanol $150-165M (similar to FY2025 + E15 uplift), India $40-60M (if OMC delays resolve), RNG $20-30M (continued ramp), 45Z credits $15-25M. That gets to $225-280M — roughly half the consensus. The Street appears to be modeling the SAF plant and/or India IPO proceeds as revenue, neither of which will contribute in 2026. Consensus recalibration to realistic levels could create an opportunity if the stock sells off on "misses" that are really just analysts correcting their models.

What They're NOT Saying

1. Third Eye Capital refinancing progress: Four quarters of "targeting H1 2026 refinancing" with zero disclosure of term sheets, lender conversations, or alternative financing arrangements. The Series A extension was only disclosed via 8-K after the amendment was signed, not previewed on any earnings call. This opacity on the single most important variable in the investment case is concerning.
2. Going concern opinion: With current liabilities exceeding total assets by $111.5M, an Altman Z-Score of -5.08, and $362M in near-term obligations, the FY2025 10-K audit should include a going concern disclosure. Management made no mention of this on the call. A going concern opinion could trigger additional covenant issues and complicate refinancing discussions.
3. MVR cost escalation: The project cost quietly moved from $30M (when the EPC was signed in September 2025) to ~$40M (disclosed on the Q4 call). No explanation was provided for the 33% cost increase. The $19.7M in grants/credits covers a smaller percentage of the new total (49% vs. 66%), increasing the out-of-pocket capital requirement.
4. India IPO filing timeline: "Targeting 2026" is unchanged from Q3. No DRHP has been filed. No investment bank mandate has been announced. No specific exchange has been named. At this rate, a 2026 India IPO appears unlikely unless the process accelerates dramatically in Q1-Q2 2026.
5. FY2025 operating cash flow: The press release did not include the full cash flow statement (deferred to the 10-K filing). Given Q1-Q3 operating cash flow was ($2.5M) — flattered by inventory drawdowns and accrued interest — the FY2025 number is critical for assessing whether the business generates or consumes cash on a normalized basis.

Market Reaction

• Pre-earnings close (Mar 11): ~$1.54
• Initial reaction (Mar 12): ~-3.25% pre-market (revenue miss headline)
• Post-earnings (Mar 13): $2.29 (+49% from pre-earnings)
• Mar 17 close: $2.47 (+60% from pre-earnings)
• Volume: Elevated; 1.42M on Mar 17 (above average)
• Analyst reactions:
  • No price target changes found within the March 13 cutoff
  • Consensus remains Strong Buy with avg PT ~$17 ($3 low / $28 high)
  • Active on earnings call: HC Wainwright (Dayal), Texas Capital (Whitfield), Stonegate (Storms)

The ~50-60% rally is the most significant positive price reaction since we initiated coverage — and it's the first time the stock rallied on earnings rather than on catalyst announcements between quarters. The market is repricing survival probability higher based on three signals: (1) the EPS beat demonstrated that 45Z credits can translate to profitability, (2) positive EBITDA suggests the underlying business can eventually cover its cost of capital, and (3) the $17M December tax credit sale proved monetization is real, not theoretical. The initial -3% dip on the revenue headline was immediately overwhelmed by buyers reacting to the profitability metrics.

At $2.47 / 65.8M shares, the market cap is ~$162M. Enterprise value ($162M + ~$490M debt + $131M preferred - $4.9M cash) is approximately $778M. The stock is up 60% from pre-earnings but still down 33% from the 52-week high of $3.66 and up only 20% from the Q3 pre-earnings price of $2.06. The market is pricing improved but still highly uncertain survival odds.

Street Perspective

Debate: Is This the Inflection Point?

Bull view: Q4 proves the thesis. Positive EBITDA, 45Z monetized, MVR under construction, LCFS recovering, RNG at segment profitability — the business model is working for the first time. The Q1-Q3 losses were the "build phase." From here, every quarter should be better: MVR online in H2 2026, additional digesters, rising LCFS, E15 demand uplift. At $2.47 with $17 average PT, the stock has 6-7x upside to consensus targets. Third Eye will extend because they always have, and the India IPO provides a liquidity catalyst.

Bear view: One quarter of $1.9M EBITDA doesn't solve a $567M liability problem. Strip out the 45Z credits and gross margin is still negative. India is unreliable. The $595M FY2026 consensus is fiction. The debt is due on demand — not "due April 1" anymore, due whenever Third Eye decides to call it. The Series A extension came with a $2M amendment fee and higher rates, showing the cost of forbearance is rising. There is no clean exit from this capital structure without massive dilution or restructuring.

Our take: Both sides are partially right. The inflection is real — the financial improvement from Q1 to Q4 is the most convincing evidence that the business model works. But "the business model works" and "the equity has value" are different statements when $567M in liabilities sits in front of a $162M equity cap. The inflection matters only if the company survives long enough for MVR and scaled RNG to fully materialize. We assign higher probability to survival than the bears but lower probability to a clean refinancing than the bulls assume.

Debate: Is $595M FY2026 Revenue Achievable?

Bull view: The SAF plant has $7B in supply contracts. If construction starts in 2026 and the plant begins partial operations, even 10-20% of capacity would add $100M+. Plus India recovery, MVR uplift, and scaled RNG. The revenue trajectory is exponential if the project pipeline delivers.

Bear view: SAF construction hasn't started. No timeline exists. India has proven it can't sustain $15M/quarter. Ethanol is a commodity business with volatile pricing. The $595M estimate is an analyst fantasy based on 5-Year Plan slides, not operational reality. Actual achievable FY2026 revenue is $225-280M.

Our take: $595M is not achievable in FY2026. We estimate $225-280M based on: ethanol $150-165M, India $40-60M, RNG $20-30M, 45Z credits $15-25M. The SAF plant is a 2028+ event. The gap between consensus and reality means every quarterly "miss" in 2026 will be noise rather than signal — investors should focus on the profitability metrics (gross margin, EBITDA, 45Z + LCFS revenue) rather than the top line.

Debate: What Is the India IPO Worth to AMTX Shareholders?

Bull view: At $100-300M valuation and 20-25% stake sale, proceeds of $20-75M go directly to parent balance sheet for debt reduction. India subsidiary has zero debt and is expanding into CBG and SAF. A successful IPO de-risks the entire capital structure and provides a valuation marker for the subsidiary.

Bear view: You can't IPO a business doing 14% utilization and $29.7M revenue (down 68% YoY). No DRHP has been filed. No investment bank is disclosed. "Targeting 2026" means nothing. Even if it happens, $20-75M against $490M in debt barely moves the needle.

Our take: The India IPO is a free option at this point — worth something if it happens, but not something we model as a high-probability near-term event. The February 2026 $24M OMC allocation is mildly positive for reviving utilization ahead of any filing. But until we see a DRHP, this remains aspirational.

Model Framework

Valuation: At $2.47 / 65.8M shares, market cap is ~$162M. EV is approximately $778M ($162M equity + ~$490M debt + $131M preferred - $4.9M cash). On our FY2026 Adj. EBITDA estimate of $0-15M (midpoint $7.5M), the stock trades at EV/EBITDA of ~104x — which underscores that this is not a fundamental value play but a survival-then-transformation bet. If the company navigates the debt wall and reaches FY2027 with MVR at full run rate, scaled RNG at 1M+ MMBtu, India at normalized utilization, and LCFS at $100+, we estimate fair value of $6-12/share. If it doesn't survive, fair value is $0. The wide range reflects the binary outcome set.

Thesis Scorecard Post-Earnings

Overall: The thesis has strengthened materially since Q3. For the first time in our coverage, more bull points are confirmed (5) than bear points (1 critical, 2 improving). The profitability inflection in Q4 is the single most important data point since we initiated coverage — it demonstrates that the business model can generate positive margins and EBITDA when 45Z credits flow. The progression from Q1 ($0.47 loss per share, $13M negative EBITDA) to Q4 ($0.08 loss, $1.9M positive EBITDA) in four quarters is striking.

But one data point doesn't erase a $567M liability stack. The thesis still comes down to one question: does the company survive the debt wall? If yes, the improving operational trajectory + MVR + scaled RNG + LCFS recovery creates a credible path to $6-12/share. If no, the equity is worthless. That binary reality, not the financial improvement, is why we maintain Hold.

Action: Maintain Hold at $2.47. Upgrade to Outperform if: (1) Third Eye Capital formally extends or refinances the core $247.9M debt facility for 12+ months, or (2) Series A Preferred is redeemed or converted on terms that don't wipe out common equity, or (3) India IPO proceeds of $20M+ are applied to debt reduction. Downgrade to Underperform if: (1) Third Eye accelerates or demands repayment, (2) going concern opinion triggers covenant default, (3) equity raise of >20% of shares outstanding (massive dilution), or (4) MVR construction halted or materially delayed beyond Q4 2026.